Adjunctive ceftaroline in combination with daptomycin or vancomycin for complicated methicillin-resistant <i>Staphylococcus aureus</i> bacteremia after monotherapy failure

Abstract

Combination therapy demonstrated success in diverse cases of refractory MRSA-B, including instances of persistent bacteremia paired with incomplete source control. Optimal timing and therapeutic cadence for combination therapy remain unclear. Our findings suggest that DAP/CPT and VAN/CPT can be considered for complicated MRSA bacteremia when other treatment options fail or are unavailable. We propose persistent bacteremia with incomplete source control to be a clinical niche particularly worthy of further investigation.